MedTrace Logo

Genoss DES in Patients With a High Risk of Ischemic Events (GENTLE Registry)

NCT05448625 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-11-25

No results posted yet for this study

Summary

This is a prospective cohort study to evaluate the long-term effect and safety of Genoss drug-eluting stents (DES) in patients with coronary artery disease with high ischemic features.

Conditions

Interventions

DEVICE

Genoss DES

The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.

Sponsors & Collaborators

  • Severance Hospital

    collaborator OTHER

  • Genoss Co., Ltd.

    collaborator INDUSTRY

  • Yonsei University

    lead OTHER

Principal Investigators

  • Deok-Kyu Cho, MD, PhD · Yongin Severance Hopistal

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-26
Primary Completion
2025-05-14
Completion
2025-09-23

Countries

  • South Korea

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05448625 on ClinicalTrials.gov